Type 1 helper T cell inflammatory signaling pathway (Th1 pathway)

The Type 1 helper T cell (Th1) inflammatory signaling pathway is a complex biological cascade central to the adaptive immune response, specifically mediating defense against intracellular pathogens (Szabo et al., 2003, Annual Review of Immunology). The pathway is primarily initiated by Interleukin-12 (IL-12) signaling through the IL-12 receptor, which activates the Signal Transducer and Activator of Transcription 4 (STAT4) and the master transcription factor T-bet (TBX21), leading to the differentiation of naive CD4+ T cells into Th1 cells (Abbas et al., 2017, Cellular and Molecular Immunology). These Th1 cells are characterized by the secretion of Interferon-gamma (IFN-gamma), a potent cytokine that activates macrophages and promotes further Th1 differentiation, creating a positive feedback loop (Schroder et al., 2004, Journal of Leukocyte Biology). While essential for pathogen clearance, chronic or excessive activation of this pathway is implicated in the pathogenesis of autoimmune diseases such as Crohn's disease, psoriasis, and rheumatoid arthritis (PubMed). Therapeutic strategies targeting this pathway include monoclonal antibodies that neutralize key cytokines like IL-12 (e.g., Ustekinumab) or small molecules that inhibit downstream signaling components like Janus kinases (e.g., Tofacitinib) (PubChem). Monitoring the activity of this pathway is often achieved through the measurement of IFN-gamma levels or the expression of Th1-associated transcription factors in clinical samples.

Other names

Th1 inflammatory signaling pathwayT-helper 1 cell signalingIL-12/IFN-gamma signaling axisTh1 differentiation pathway

Inhibition of IL-12/IL-23 p40 subunit, Janus kinase inhibition, and Interferon-gamma receptor modulation.